Investing Profile

Pablo Lubroth(475)

VCAngelInvestorOperator
General Partner at Interlagos
hummingbird.vc/the-teamNew York, New York
Photo of Pablo Lubroth, General Partner at Interlagos Capital
Your Intro Paths to Pablo Lubroth

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Pablo Lubroth's investing connections

Picture
Picture
Picture

11 Investors

Connected to Ian Rountree (Cantos Ventures), Nabeel Hyatt (Spark Capital), Mar Hershenson (Pear VC), and 8 other investors on Signal.

Networks Pablo is a member of
University of Cambridge Network
258 CONNECTIONS
UCL Network
104 CONNECTIONS
UCL Network
104 CONNECTIONS
Johnson & Johnson Network
57 CONNECTIONS
University of Cambridge Network
30 CONNECTIONS

Find Pablo Lubroth on

cb
Current Investing Position
Interlagos Capital General Partner
Investment Range
$500K - $5.0M
Sweet Spot
$2.8M
Investments On Record
8

Pablo Lubroth is on these Sector & Stage Rankings

Pharmaceuticals (Seed)BioTech (Series B)Consumer Health (Seed)Consumer Health (Series B)Direct-to-Consumer (DTC) (Series A)Hardware (Seed)Diverse InvestorsHardware (Series B)Hardware (Series A)Consumer Health (Series A)AI (Series B)AI (Series A)Angel, Scout, and Solo-CapitalistsDirect-to-Consumer (DTC) (Seed)Direct-to-Consumer (DTC) (Series B)Hardware (Pre-seed)Direct-to-Consumer (DTC) (Pre-seed)Consumer Health (Pre-seed)AI (Pre-seed)AI (Seed)BioTech (Seed)Pharmaceuticals (Series B)BioTech (Series A)Pharmaceuticals (Series A)New York CityLondonDigital Health (Series B)DeepTech (Series B)DeepTech (Series A)DeepTech (Seed)Pharmaceuticals (Pre-seed)DeepTech (Pre-seed)Digital Health (Pre-seed)BioTech (Pre-seed)Therapeutics (Series A)Therapeutics (Seed)Therapeutics (Series B)Therapeutics (Pre-seed)Digital Health (Series A)Digital Health (Seed)

Pablo Lubroth's Investments On Record (6)

CompanyStageDateRound SizeTotal Raised
Waypoint Bio
SeedJun 2024$15M
$15M
Enveda Biosciences
Series BDec 2022$55M
Series AJun 2021$51M
$500M
Co-investors: Rohit Sharma (True Ventures), Pegah Ebrahimi (FPV Ventures), Zavain Dar (Dimension Capital), Christian Scherrer (Kinnevik), Matthew De Silva (Builders VC), rajiv chegu (Serent Capital), Henry Kravis, Chris Gibson
Kaleidoscope
SeedSep 2022$6M
$22M
Co-investors: Justin Kaufenberg (Rally Ventures), Jeff Hinck (Rally Ventures), Adam Goulburn (Dimension Capital), Nitesh Banta (Stellar Capital), Daren Cotter, Chris Gibson
NanoSyrinx
SeedJul 2021$8M
Pre SeedSep 2020
$21M
Co-investors: Lucy Edwardes-Jones (Business Growth Fund), Uzma Choudry (Octopus Ventures), Jonathan Milner
MFX
SeedApr 2020$2M
$2M
Pencil Biosciences
SeedDec 2019$670K
$7.7M
Co-investors: Jonathan Milner

Pablo Lubroth's Experience

Analyst | J&J Innovation Johnson & JohnsonPresent
Investor Future Planet CapitalPresent
Investment Manager UKI2S | Future Planet CapitalPresent
Investor and Board Director NanoSyrinxPresent
Venture Partner InterlagosPresent
General Partner InterlagosPresent
Research UCLPresent
Corporate Development Horizon DiscoveryPresent
Co-Founder & Director Decoding BioPresent
EIR, VP Special Projects EnvedaPresent
Investor Hummingbird VenturesPresent
Investor & Board Observer EnvedaPresent
VP Special Projects EnvedaPresent
Business Development BenevolentAIPresent
Co-Founder & Editor Decoding BioPresent
Investment Team Future Planet CapitalPresent
Investment Team Hummingbird VenturesPresent
Research University of CambridgePresent
Co-Founder Hera BiotechPresent
Co-Founder Decoding BioPresent
Investor and Board Observer EnvedaPresent
EIR and VP Special Projects EnvedaPresent
Corporate Development Associate Horizon DiscoveryPresent
Research Assistant | Molecular Neuroscience University of CambridgePresent
Research Assistant | Metabolic Pharmacology University College LondonPresent
Investor EnvedaPresent
Investor and Board Observer Kaleidoscope.bioPresent
Investor and Board Observer Kernal Biologics, Inc.Present
Investor Waypoint BioPresent
Investor Ladder TherapeuticsPresent

Pablo Lubroth's Education

UCL MSc Biochemical Engineering
UCL BSc Pharmacology, Neuroscience
University of Cambridge MPhil Bioscience Enterprise